Cited by 20Genomics and Rare DiseasesGenomics and Phylogenetic StudiesGenetic Associations and Epidemiology

Evaluation of a whole‐exome sequencing pipeline and benchmarking of causal germline variant prioritizers

Tosco‐Herrera, Eva, Muñoz‐Barrera, Adrián, Jáspez, David, Rubio‐Rodríguez, Luis A., Mendoza‐Alvarez, Alejandro, Rodriguez‐Perez, Hector, Jou, Jonathan, Iñigo‐Campos, Antonio +9 more·2022·Human Mutation

Abstract

Most causal variants of Mendelian diseases are exonic. Whole-exome sequencing (WES) has become the diagnostic gold standard, but causative variant prioritization constitutes a bottleneck. Here we assessed an in-house sample-to-sequence pipeline and benchmarked free prioritization tools for germline causal variants from WES data. WES of 61 unselected patients with a known genetic disease cause was obtained. Variant prioritizations were performed by diverse tools and recorded to obtain a diagnostic yield when the causal variant was present in the first, fifth, and 10th top rankings. A fraction of causal variants was not captured by WES (8.2%) or did not pass the quality control criteria (13.1%). Most of the applications inspected were unavailable or had technical limitations, leaving nine tools for complete evaluation. Exomiser performed best in the top first rankings, while LIRICAL led in the top fifth rankings. Based on the more conservative top 10th rankings, Xrare had the highest diagnostic yield, followed by a three-way tie among Exomiser, LIRICAL, and PhenIX, then followed by AMELIE, TAPES, Phen-Gen, AIVar, and VarNote-PAT. Xrare, Exomiser, LIRICAL, and PhenIX are the most efficient options for variant prioritization in real patient WES data.

Integrity signals

Registry

Crossref · 10.1002/humu.24459

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • LIRICAL, XRare, and Exomiser are the strongest performing approaches in a prior comparison of gene prioritization tools.

    “LIRICAL, XRare, and Exomiser are the strongest performing approaches in a prior comparison of gene prioritization tools121, and Exomiser is currently in use at multiple UDN sites50.”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Tosco‐Herrera, E., Muñoz‐Barrera, A., Jáspez, D., Rubio‐Rodríguez, L. A., Mendoza‐Alvarez, A., Rodriguez‐Perez, H., Jou, J., Iñigo‐Campos, A., Corrales, A., Ciuffreda, L., Martinez‐Bugallo, F., Prieto‐Morin, C., García‐Olivares, V., González‐Montelongo, R., Lorenzo‐Salazar, J. M., Marcelino‐Rodriguez, I., & Flores, C.
Affiliations
  • Research Unit Hospital Universitario Nuestra Señora de Candelaria (HUNSC) Santa Cruz de Tenerife Spain
  • Universidad de La Laguna (ES)
  • Instituto Tecnológico y de Energías Renovables (ES)
  • Peoria campus of the University of Illinois System (US)
  • Genomics Division Instituto Tecnológico y de Energías Renovables (ITER) Granadilla de Abona Spain
  • Instituto de Salud Carlos III (ES)
  • Hospital Universitario Nuestra Señora de Candelaria (ES)
  • Clinical Analysis Service Hospital Universitario Nuestra Señora de Candelaria (HUNSC) Santa Cruz de Tenerife Spain
  • Escuela de Doctorado y Estudios de Posgrado de la Universidad de La Laguna (EDEPULL) Universidad de La Laguna (ULL) San Cristóbal de La Laguna Spain
Corresponding author
Flores, Carlos
Venue
Human Mutation
Publisher
Wiley
Published
2022-09-12
Volume
43
Issue
12
Pages
2010-2020
ISSN
  • 1059-7794 (ISSN-L)
  • 1098-1004
OpenAlex
W4294354883
Cited by
20
References
2
Citations by year
2026: 3 · 2025: 5 · 2024: 8 · 2023: 4
FWCI
2.56
Type
journal article
Language
en
Open access
closed
Locations
  • Human Mutation (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Agencia Canaria de Investigación, Innovación y Sociedad de la Información (TESIS2020010002)
  • Ministerio de Ciencia e Innovación (RTC‐2017‐6471‐1)
  • Instituto de Salud Carlos III (FI18/00230, CD19/00231, PI20/00876)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Phylogenetic Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
Keywords
exome sequencing, variant prioritization, monogenic disorders, diagnostic yield, benchmarking, Exomiser, PHENIX, Amélie, Tapes, quality control
MeSH terms
Exome Sequencing, Humans, Germ-Line Mutation, Exome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review